KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial.

D Baron, T Pace Loscos, R Schiappa, N Barbet, E Dost, S Ben Dhia, S Soltani, L Mineur, I Martel, S Horn, C Picardi, A Stewart, E Cotte, R Coquard, G Baudin, L Evesque, A Dhadda, A Sun Myint, J P Gérard, J Doyen, ICONE group

Ann Oncol 36(2) 208-215

PMID39532203
PMCID-
DOI10.1016/j.annonc.2024.10.827
发表日期2024-11-12
入排依据:The trial is a Phase III randomized trial in human oncology with a drug intervention (capecitabine), but the primary efficacy endpoint is organ preservation rate (a binary outcome), not a standard time-to-event endpoint (OS, PFS, DFS, etc.). While local regrowth is a time-to-event outcome, it is not presented as a primary or key secondary endpoint with Kaplan-Meier analysis or hazard ratios in the abstract. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort focused on time-to-event efficacy endpoints.
摘要

摘要

BACKGROUND: The OPERA trial has shown that a contact X-ray brachytherapy 50 kV (CXB) boost with neoadjuvant chemoradiotherapy (NCRT) can increase organ preservation (OP) rate for early rectal adenocarcinoma (ADK) of low-mid rectum. We report the results after 5 years of follow-up. PATIENTS AND METHODS: OPERA was a multicentre, phase III trial that included operable patients (pts), with cT2-cT3b low-mid rectal ADK, tumours <5 cm, cN0 or cN1 <8 mm. All pts received external beam radiotherapy (EBRT): 45 Gy in 25 fractions with concurrent capecitabine. Pts were randomly assigned (1:1) to receive a boost of EBRT in group A (9 Gy/5 fractions) or a boost with CXB (90 Gy/3 fractions) in group B. The primary end point was OP rate. RESULTS: Out of 148 patients randomised, 141 were eligible. Between week 14-24, a clinical complete (or near) response was observed in 44 pts in group A (64%) versus 66 in group B (92%); P < 0.001. The 3-year OP rate was 59% in group A versus 81% in group B (P = 0.003). After update the median follow-up was 61.1 months [56.8-64.5]. The 5-year local regrowth was 39% in group A and 17% in group B (P = 0.1). The difference in OP was still highly significant between both groups: A 56% versus B 79% (P = 0.004). The difference was more significant if tumours <3 cm, with an OP rate of 93% in group B compared to 54% in group A. Of the 28 local regrowths, 3 occurred after 3 years of follow-up. Rectal bleeding (grade 1-2), which was the most prevalent toxicity during follow-up, disappeared most of the time after three years. Bowel function was not worsened by the CXB boost. CONCLUSION: The OPERA trial was the first trial to demonstrate that CXB dose escalation was increasing the OP rate with good bowel function at 3 years. At 5 years, these results are sustained, especially in small early-stage tumours. The occurrence of some local regrowth after 3 years necessitates close surveillance of these pts during the 5-year period.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。